Vera Therapeutics, Inc. (NASDAQ:VERA) Shares Sold by Axa S.A.

Axa S.A. decreased its stake in shares of Vera Therapeutics, Inc. (NASDAQ:VERA) by 9.5% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 246,201 shares of the company’s stock after selling 25,877 shares during the quarter. Axa S.A. owned about 0.45% of Vera Therapeutics worth $8,908,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Public Employees Retirement Association of Colorado purchased a new stake in shares of Vera Therapeutics during the second quarter valued at $135,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in Vera Therapeutics during the 2nd quarter valued at about $163,000. Ameritas Investment Partners Inc. increased its holdings in shares of Vera Therapeutics by 20.8% in the first quarter. Ameritas Investment Partners Inc. now owns 4,000 shares of the company’s stock valued at $172,000 after purchasing an additional 688 shares during the period. Cetera Advisors LLC acquired a new position in shares of Vera Therapeutics in the first quarter valued at about $235,000. Finally, Capstone Investment Advisors LLC purchased a new position in shares of Vera Therapeutics in the first quarter worth about $248,000. Hedge funds and other institutional investors own 99.21% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently commented on the company. Cantor Fitzgerald reiterated an “overweight” rating and issued a $107.00 target price on shares of Vera Therapeutics in a research report on Monday, September 23rd. Evercore ISI upgraded shares of Vera Therapeutics to a “strong-buy” rating in a research note on Monday, September 16th. Finally, JPMorgan Chase & Co. boosted their target price on shares of Vera Therapeutics from $62.00 to $72.00 and gave the company an “overweight” rating in a research report on Tuesday, September 3rd. One investment analyst has rated the stock with a hold rating, six have given a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $51.75.

Vera Therapeutics Stock Down 4.9 %

Shares of NASDAQ VERA opened at $43.44 on Friday. The company has a current ratio of 21.43, a quick ratio of 21.43 and a debt-to-equity ratio of 0.15. The company has a 50-day moving average of $38.40 and a 200 day moving average of $39.11. Vera Therapeutics, Inc. has a 12-month low of $9.24 and a 12-month high of $50.78. The stock has a market cap of $2.38 billion, a PE ratio of -21.19 and a beta of 0.99.

Vera Therapeutics (NASDAQ:VERA) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.06). As a group, sell-side analysts predict that Vera Therapeutics, Inc. will post -2.57 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Marshall Fordyce sold 14,471 shares of the business’s stock in a transaction dated Wednesday, August 21st. The shares were sold at an average price of $39.76, for a total transaction of $575,366.96. Following the transaction, the chief executive officer now owns 322,667 shares of the company’s stock, valued at approximately $12,829,239.92. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. In other news, CEO Marshall Fordyce sold 14,471 shares of Vera Therapeutics stock in a transaction that occurred on Wednesday, August 21st. The shares were sold at an average price of $39.76, for a total transaction of $575,366.96. Following the sale, the chief executive officer now owns 322,667 shares of the company’s stock, valued at approximately $12,829,239.92. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Beth C. Seidenberg sold 1,177 shares of the company’s stock in a transaction that occurred on Wednesday, September 18th. The shares were sold at an average price of $42.01, for a total value of $49,445.77. Following the completion of the transaction, the director now owns 160,376 shares in the company, valued at $6,737,395.76. The disclosure for this sale can be found here. Insiders sold 54,398 shares of company stock valued at $2,275,656 in the last three months. 21.70% of the stock is currently owned by insiders.

About Vera Therapeutics

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.